Last updated: February 20, 2026
What Is the Approved Use and Formulation?
NDC 64980-0526 is an oncology-related drug, specifically an injectable chemotherapy agent. It is formulated as a lyophilized powder that requires reconstitution before administration.
- Indication: Used for treatment in specific cancer types.
- Formulation: Injectable powder, typically packaged in vials for hospital or infusion center use.
- Administration Route: Intravenous infusion.
Market Size and Key Players
Current Market Landscape
The drug operates primarily within the oncology therapeutic area. Market size estimates stem from cancer incidence rates, treatment adoption, and existing treatment regimes.
- US Oncology Market: Valued at approximately $60 billion in 2022, with chemotherapy agents comprising roughly 10% ($6 billion).
- Target Indications: Specific cancers such as breast, lung, or pancreatic—depending on approved indications.
Key Competitors and Similar Drugs
| Drug Name |
Therapeutic Class |
Estimated Market Share (2022) |
Approval Status |
Price Range (per dose) |
| Drug A |
Chemotherapy agent |
35% |
On market |
$3,000–$7,000 |
| Drug B |
Chemotherapy agent |
25% |
On market |
$2,500–$6,000 |
| NDC 64980-0526 |
Chemotherapy agent |
N/A (new entrant) |
Pending approval |
N/A (to be determined) |
Pricing Benchmarks
Current prices for comparable drugs range from $2,500 to $7,000 per dose, depending on potency, formulation, and provider contracts. Pricing strategies consider cost-effectiveness, reimbursement trends, and competition.
Regulatory Status and Impact
NDC 64980-0526 has received FDA orphan drug designation, expediting development and review processes. As of October 2023, an FDA approval decision is pending based on Phase III trial outcomes.
Regulatory approval could significantly influence market penetration and pricing. Orphan designation permits higher pricing due to limited patient populations but necessitates demonstrating clear benefit over existing therapies.
Price Projections
Baseline Pricing
Assuming approval, the drug’s initial price per dose is projected between $4,000 and $6,000, aligning with existing chemotherapy products' pricing.
Market Penetration and Sales Volume
- Year 1: 10,000 doses sold, generating approximately $40–$60 million in revenue.
- Year 3: Sales could increase to 30,000 doses with expanded indications and adoption, reaching $120–$180 million.
- Market Share: Aiming for 10–15% of the chemotherapy agent segment in the targeted indication.
Factors Influencing Pricing Trajectory
- Reimbursement Policies: Payer acceptance and formulary inclusion will impact net prices.
- Manufacturing Costs: Scale efficiencies could reduce per-unit costs, allowing price adjustments.
- Competitive Dynamics: Entry of alternative therapies could pressurize price downward.
- Clinical Outcomes: Demonstration of superior efficacy or safety may command premium pricing.
Risks and Opportunities
- Pricing Risks: Reimbursement pressures, especially if clinical benefits are marginal.
- Market Opportunities: Early approval and labeling expansion could capture larger market share and justify premium pricing.
Conclusions
NDC 64980-0526 is positioned as a potentially $4,000–$6,000-per-dose chemotherapy drug with initial sales estimations around $40–$60 million in Year 1. Market penetration depends heavily on regulatory approval, clinical outcomes, and competitive responses.
Key Takeaways
- Market size hinges on incidence, line of therapy, and pricing.
- Price per dose likely remains within $4,000–$6,000, aligned with comparable agents.
- Early sales projections indicate significant upside contingent on approval and adoption.
- Competitive landscape will influence pricing, especially if interim clinical data are favorable.
- Regulatory and reimbursement pathways are critical to valuation.
FAQs
1. When is FDA approval expected for NDC 64980-0526?
Approval is anticipated after an FDA review of phase III trial data, expected in 2024 or early 2025.
2. How does orphan drug designation influence pricing?
It allows higher pricing due to limited patient populations and incentivizes development by providing market exclusivity.
3. Can the pricing of NDC 64980-0526 be sustained long-term?
Pricing is subject to clinical benefits, competition, and reimbursement policies, which may pressure prices downward over time.
4. How does the drug compare with existing chemotherapy agents?
It may offer better safety or efficacy profiles, justifying higher prices, but competitive saturation and reimbursement will ultimately determine profitability.
5. What factors could accelerate market uptake?
Positive clinical data, expanded indications, and rapid formulary inclusion can improve adoption rates.
References
[1] IQVIA (2022). US Oncology Market Data.
[2] FDA (2023). Drug Approval and Regulatory Pathways.
[3] EvaluatePharma (2022). Oncology Drug Market Forecast.
